North American Report

Interstitial Cystitis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

 Breaking News
  • No posts were found

Interstitial Cystitis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

October 20
12:22 2021
Interstitial Cystitis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working
DelveInsight Business Research LLP
DelveInsight’s “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Interstitial Cystitis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Interstitial Cystitis Market Report:

  • The total diagnosed prevalent population of IC in the seven major markets was found to be  2,343,164 in 2018, wherein the diagnosed prevalent cases of IC patients in the United States were found to be 1,512,368 in 2018.

  • IC can be divided into three types based on severity, namely, mild, moderate, and severe type. DelveInsight, after analyzing the severity-based data for IC was found that in the United States, the number of cases of mild, moderate, and severe was  544,452, 756,184, and 211,732, respectively, in 2018.

  • Type-specific data for IC has also been analyzed by Delvelnsight. IC can be divided into two types based on this data, namely, Non-ulcerative and Ulcerative types. It was found that in the United States, the number of cases of the non-ulcerative and ulcerative type of IC was  1,361,131 and 151,237, respectively, in 2018.

Key benefits of the report:

  1. Interstitial Cystitis market report covers a descriptive overview and comprehensive insight of the Interstitial Cystitis Epidemiology and Interstitial Cystitis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Interstitial Cystitis market report provides insights on the current and emerging therapies.

  3. Interstitial Cystitis market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Interstitial Cystitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market.

Got queries? Click here to know more about the Interstitial Cystitis Market Landscape.

Interstitial Cystitis Overview

Interstitial Cystitis (IC), also called Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. The bladder is a hollow, muscular organ that stores urine, which expands until it is full and then gives signals to the brain that it is time to urinate, communicating through the pelvic nerves; this creates the urge to urinate for most people. With IC, these signals get mixed up, and then patients feel the need to urinate more often and with smaller volumes of urine than most people. This condition most often affects women and can have a long-lasting impact on their quality of life. Although there is no cure, medications and other therapies may offer some relief.

Interstitial Cystitis Market 

The dynamics of the Interstitial Cystitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Seikagaku Corporation, Astellas Pharma, and others during the forecasted period 2018-2030.

Interstitial Cystitis Pipeline Therapies and Key Companies 

  • KRP-116D: Kyorin Pharmaceutical

  • Certolizumab pegol (Cimzia): UCB Pharma

  • LP-08: Lipella Pharmaceuticals

  • SI-722: Seikagaku Corporation

  • ASP6294: Astellas Pharma

Interstitial Cystitis Market Drivers 

  • FDA approved Oral medication 

  • Increasing emerging therapies

  • Increasing awareness

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Interstitial Cystitis Patient Share (%) Overview at a Glance

5. Interstitial Cystitis Market Overview at a Glance

6. Interstitial Cystitis Disease Background and Overview

7. Interstitial Cystitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Cystitis 

9. Interstitial Cystitis Current Treatment and Medical Practices

10. Unmet Needs

11. Interstitial Cystitis Emerging Therapies

12. Interstitial Cystitis Market Outlook

13. Country-Wise Interstitial Cystitis Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Interstitial Cystitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Interstitial Cystitis Market Outlook 2030. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/